JP2018528257A5 - - Google Patents

Download PDF

Info

Publication number
JP2018528257A5
JP2018528257A5 JP2018521190A JP2018521190A JP2018528257A5 JP 2018528257 A5 JP2018528257 A5 JP 2018528257A5 JP 2018521190 A JP2018521190 A JP 2018521190A JP 2018521190 A JP2018521190 A JP 2018521190A JP 2018528257 A5 JP2018528257 A5 JP 2018528257A5
Authority
JP
Japan
Prior art keywords
seq
group
amino acid
terminus
peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018521190A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018528257A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/041544 external-priority patent/WO2017011312A1/en
Publication of JP2018528257A publication Critical patent/JP2018528257A/ja
Publication of JP2018528257A5 publication Critical patent/JP2018528257A5/ja
Priority to JP2021137990A priority Critical patent/JP7378446B2/ja
Priority to JP2023123206A priority patent/JP2023153906A/ja
Priority to JP2025144586A priority patent/JP2025172117A/ja
Priority to JP2025163923A priority patent/JP2025185000A/ja
Pending legal-status Critical Current

Links

JP2018521190A 2015-07-10 2016-07-08 疎水性薬剤の効能を改善するための配合物 Pending JP2018528257A (ja)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2021137990A JP7378446B2 (ja) 2015-07-10 2021-08-26 疎水性薬剤の効能を改善するための配合物
JP2023123206A JP2023153906A (ja) 2015-07-10 2023-07-28 疎水性薬剤の効能を改善するための配合物
JP2025144586A JP2025172117A (ja) 2015-07-10 2025-09-01 疎水性薬剤の効能を改善するための配合物
JP2025163923A JP2025185000A (ja) 2015-07-10 2025-09-30 疎水性薬剤の効能を改善するための配合物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562190909P 2015-07-10 2015-07-10
US62/190,909 2015-07-10
PCT/US2016/041544 WO2017011312A1 (en) 2015-07-10 2016-07-08 Formulations for improving the efficacy of hydrophobic drugs

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021137990A Division JP7378446B2 (ja) 2015-07-10 2021-08-26 疎水性薬剤の効能を改善するための配合物

Publications (2)

Publication Number Publication Date
JP2018528257A JP2018528257A (ja) 2018-09-27
JP2018528257A5 true JP2018528257A5 (https=) 2019-08-15

Family

ID=57758158

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2018521190A Pending JP2018528257A (ja) 2015-07-10 2016-07-08 疎水性薬剤の効能を改善するための配合物
JP2021137990A Active JP7378446B2 (ja) 2015-07-10 2021-08-26 疎水性薬剤の効能を改善するための配合物
JP2023123206A Pending JP2023153906A (ja) 2015-07-10 2023-07-28 疎水性薬剤の効能を改善するための配合物
JP2025144586A Pending JP2025172117A (ja) 2015-07-10 2025-09-01 疎水性薬剤の効能を改善するための配合物
JP2025163923A Pending JP2025185000A (ja) 2015-07-10 2025-09-30 疎水性薬剤の効能を改善するための配合物

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2021137990A Active JP7378446B2 (ja) 2015-07-10 2021-08-26 疎水性薬剤の効能を改善するための配合物
JP2023123206A Pending JP2023153906A (ja) 2015-07-10 2023-07-28 疎水性薬剤の効能を改善するための配合物
JP2025144586A Pending JP2025172117A (ja) 2015-07-10 2025-09-01 疎水性薬剤の効能を改善するための配合物
JP2025163923A Pending JP2025185000A (ja) 2015-07-10 2025-09-30 疎水性薬剤の効能を改善するための配合物

Country Status (12)

Country Link
US (1) US10532105B2 (https=)
EP (1) EP3319980B8 (https=)
JP (5) JP2018528257A (https=)
KR (1) KR20180027532A (https=)
CN (1) CN108350036B (https=)
AU (1) AU2016291597B2 (https=)
CA (1) CA2991655A1 (https=)
DK (1) DK3319980T3 (https=)
EA (1) EA201890271A1 (https=)
IL (1) IL256486B2 (https=)
MX (1) MX384254B (https=)
WO (1) WO2017011312A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018528257A (ja) * 2015-07-10 2018-09-27 ペプティノボ・バイオファーマ・リミテッド・ライアビリティ・カンパニーPeptinovo Biopharma, LLC 疎水性薬剤の効能を改善するための配合物
US11174288B2 (en) 2016-12-06 2021-11-16 Northeastern University Heparin-binding cationic peptide self-assembling peptide amphiphiles useful against drug-resistant bacteria
KR20220045203A (ko) * 2019-08-13 2022-04-12 펩티노보 바이오파마, 인크. 암 치료에 따른 화학요법-유도된 말초 신경병증 치료를 위한 palm
EP4196166A4 (en) * 2020-08-11 2024-10-09 Peptinovo Biopharma Inc. PEPTIDES AND FORMULATIONS FOR CANCER TREATMENT

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6004925A (en) 1997-09-29 1999-12-21 J. L. Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6046166A (en) 1997-09-29 2000-04-04 Jean-Louis Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6287590B1 (en) 1997-10-02 2001-09-11 Esperion Therapeutics, Inc. Peptide/lipid complex formation by co-lyophilization
US6664230B1 (en) 2000-08-24 2003-12-16 The Regents Of The University Of California Orally administered peptides to ameliorate atherosclerosis
US8568766B2 (en) 2000-08-24 2013-10-29 Gattadahalli M. Anantharamaiah Peptides and peptide mimetics to treat pathologies associated with eye disease
US20040234588A1 (en) 2000-09-21 2004-11-25 University Of Georgia Research Foundation, Inc. Artificial lipoprotein carrier system for bioactive materials
AUPR798901A0 (en) 2001-09-28 2001-10-25 Medvet Science Pty. Ltd. Spheroidal hdl particles with a defined phospholipid composition
JP2006507223A (ja) 2002-05-17 2006-03-02 エスペリオン セラピューティクス,インコーポレイテッド 脂質代謝異常疾患の治療方法
JP4995423B2 (ja) 2002-12-03 2012-08-08 ブランシェット・ロックフェラー・ニューロサイエンスィズ・インスティテュート 物質を血液−脳関門を渡って輸送するための人工低密度リポタンパク質キャリア
US8097283B2 (en) 2004-01-15 2012-01-17 Mount Sinai School Of Medicine Methods and compositions for imaging
GB0525214D0 (en) 2005-12-12 2006-01-18 Bioinvent Int Ab Biological materials and uses thereof
MX2009010683A (es) * 2007-04-05 2010-01-20 Wyeth Corp Conjugado de wortmanina-rapamicina y usos del mismo.
US20090110739A1 (en) * 2007-05-15 2009-04-30 University Of North Texas Health Science Center At Forth Worth Targeted cancer chemotherapy using synthetic nanoparticles
WO2009055538A1 (en) 2007-10-23 2009-04-30 The Cleveland Clinic Foundation Oxidant resistant apolipoprotein a-1 and mimetic peptides
WO2009059450A1 (en) * 2007-11-05 2009-05-14 Shanghai Jiaotong University Peptide ligand directed drug delivery
CN105903029A (zh) 2007-12-12 2016-08-31 大学健康网络 高密度脂蛋白样肽磷脂支架(“hpps”)纳米颗粒
CA2721333C (en) * 2008-04-15 2020-12-01 Protiva Biotherapeutics, Inc. Novel lipid formulations for nucleic acid delivery
WO2009155366A2 (en) * 2008-06-18 2009-12-23 The Regents Of The University Of California Improved peptide mediators of cholesterol efflux
ES3029483T3 (en) * 2008-09-17 2025-06-24 Endocyte Inc Folate receptor binding conjugates of antifolates
US8603999B2 (en) 2008-12-05 2013-12-10 Commonwealth Scientific And Industrial Research Organisation Amphiphile prodrugs
EP2658993B1 (en) * 2010-12-31 2014-10-01 Alphacore Pharma LLC Detection of lcat activity
JP2014132832A (ja) * 2011-05-10 2014-07-24 Sekisui Chem Co Ltd 医薬、機能性食品、目的蛋白質の安定化方法、融合蛋白質、核酸、並びに、組換え体
EP2861256B1 (en) * 2012-06-15 2019-10-23 The Brigham and Women's Hospital, Inc. Compositions for treating cancer and methods for making the same
CN103393597B (zh) * 2013-07-02 2015-06-17 北京大学 疏水性肽修饰的注射用长循环脂质体给药系统
CN104558117B (zh) * 2013-10-25 2018-01-16 复旦大学 一种乙酰胆碱受体介导靶向的d构型多肽及其应用
US10220046B2 (en) 2014-07-14 2019-03-05 The Regents Of The University Of Michigan Compositions and methods for disease treatment using nanoparticle delivered compounds
WO2016019333A1 (en) 2014-07-31 2016-02-04 Kinemed, Inc. The effect of phospholipid composition of reconstituted hdl on its cholesterol efflux and anti-inflammatory properties
JP2018528257A (ja) * 2015-07-10 2018-09-27 ペプティノボ・バイオファーマ・リミテッド・ライアビリティ・カンパニーPeptinovo Biopharma, LLC 疎水性薬剤の効能を改善するための配合物

Similar Documents

Publication Publication Date Title
CN107337728B (zh) 脂蛋白复合物及其制备和用途
ES2342258T3 (es) Peptidos administrados oralmente para mejorar la aterosclerosis.
JP2012518006A5 (https=)
JP2018528257A5 (https=)
US11434267B2 (en) Peptides having reduced toxicity that stimulate cholesterol efflux
JP2011507807A5 (https=)
KR101993937B1 (ko) 염증 억제용 펩티드
MY155029A (en) Peptide vaccines for cancers expressing tumor-associated antigens
US20230302145A1 (en) Surfactant protein c mimics displaying pathogen- or allergen-binding moieties
CN110612097B (zh) 脂质体药物递送媒介物
JP2011525181A (ja) コレステロール流出の改良型ペプチドメディエータ
US7153490B2 (en) Liposomes encapsulating anticancer drugs and use thereof in the treatment of malignant tumors
JP6810690B2 (ja) 疾患組織に対する選択性を有するファルマコフォアを含む組成物およびその生成方法
US20050058697A1 (en) Cell penetrating therapeutic agents
CA3127985A1 (en) Bi-specific extracellular matrix binding peptides and methods of use thereof
EP1359941A2 (en) Albumin-based drug delivery system and antimicrobial peptides
KR20180027532A (ko) 소수성 약물의 효능 개선용 제형
JP2022544262A5 (https=)
CN111164094B (zh) 抗癌肽及其用途
Chiangjong et al. Membrane Attacking Peptides: A New Involving Cancer Therapy
Dathe et al. 28 Cellular Uptake of Liposomal and Micellar Carriers Mediated by ApoE-Derived Peptides
CN104248768A (zh) 靶向中枢神经系统的纳米药物载体
WO2012014046A2 (en) Supramolecular aggregates as drug carriers on cell expressing receptors for branched neurotensin
NZ613524B2 (en) Lipoprotein complexes and manufacturing and uses thereof